What can rodent models tell us about apathy and associated neuropsychiatric symptoms in parkinson’s disease?

Translational Psychiatry

Volumn 6, Issue 3, 2016, Pages

  Magnard, R ^a,b   Vachez, Y ^a,b   Carcenac, C ^a,b   Krack, P ^a,b,c   David, O ^a,b   Savasta, M ^a,b   Boulet, S ^a,b   Carnicella, S ^a,b  

^a INSERM   (France)

^b UNIV GRENOBLE ALPES   (France)

^c GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ANTIPARKINSON AGENT; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; OXIDOPAMINE; BENZOTHIAZOLE DERIVATIVE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; PRAMIPEXOLE;

ANHEDONIA; ANIMAL BEHAVIOR; ANIMAL MODEL; ANXIETY; APATHY; BEHAVIOR DISORDER; BRAIN DAMAGE; DEPRESSION; DISEASE ASSOCIATION; DOPAMINERGIC SYSTEM; MEDIAL FOREBRAIN BUNDLE; MENTAL DISEASE; MESOLIMBIC DOPAMINERGIC SYSTEM; MOTIVATION; MPTP-INDUCED PARKINSONISM; NEUROPATHOLOGY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PHARMACEUTICAL CARE; RAT; REVIEW; RODENT MODEL; SYMPTOM; AGONISTS; ANIMAL; DISEASE MODEL; DRUG EFFECTS; METABOLISM; MOUSE; NEOSTRIATUM; PATHOPHYSIOLOGY; PSYCHOLOGY; SUBSTANTIA NIGRA;

ANHEDONIA; ANIMALS; ANXIETY; APATHY; BEHAVIOR, ANIMAL; BENZOTHIAZOLES; DEPRESSION; DISEASE MODELS, ANIMAL; DOPAMINE AGONISTS; MICE; NEOSTRIATUM; PARKINSON DISEASE; RATS; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; SUBSTANTIA NIGRA;

EID: 85016587894     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2016.17     Document Type: Review

References (141)

1. Aarsland D, Marsh L, Schrag A. Neuropsychiatric symptoms in Parkinson's dis-ease. Mov Disord 2009; 24: 2175–2186.
2. Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 2006; 5: 235–245.
3. Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009; 8: 464–474.
4. Voon V, Mehta AR, Hallett M. Impulse control disorders in Parkinson's disease: recent advances. Curr Opin Neurol 2011; 24: 324–330.
5. Sierra M, Carnicella S, Strafella AP, Bichon A, Lhommee E, Castrioto A et al. Apathy and impulsive control disorders: Yin & Yang of dopamine dependent behaviors. J Parkinsons Dis 2015; 5: 625–636.
6. Bastide MF, Meissner WG, Picconi B, Fasano S, Fernagut PO, Feyder M et al. Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease. Prog Neurobiol 2015; 132: 96–168.
7. Pagonabarraga J, Kulisevsky J, Strafella AP, Krack P. Apathy in Parkinson's dis-ease: clinical features, neural substrates, diagnosis, and treatment. Lancet Neurol 2015; 14: 518–531.
8. Marin RS. Differential diagnosis and classification of apathy. Am J Psychiatry 1990; 147: 22–30.
9. Thobois S, Ardouin C, Lhommee E, Klinger H, Lagrange C, Xie J et al. Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation. Brain 2010; 133: 1111–1127.
10. Remy P, Doder M, Lees A, Turjanski N, Brooks D. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 2005; 128: 1314–1322.
11. Starkstein SE, Brockman S. Apathy and Parkinson's disease. Curr Treat Options Neurol 2011; 13: 267–273.
12. Pedersen KF, Alves G, Bronnick K, Aarsland D, Tysnes OB, Larsen JP. Apathy in drug-naive patients with incident Parkinson's disease: the Norwegian ParkWest study. J Neurol 2009; 257: 217–223.
13. Houeto JL, Mesnage V, Mallet L, Pillon B, Gargiulo M, du Moncel ST et al. Behavioural disorders, Parkinson's disease and subthalamic stimulation. J Neurol Neurosurg Psychiatry 2002; 72: 701–707.
14. Castrioto A, Lhommee E, Moro E, Krack P. Mood and behavioural effects of subthalamic stimulation in Parkinson's disease. Lancet Neurol 2014; 13: 287–305.
15. Lewis CJ, Maier F, Eggers C, Pelzer EA, Maarouf M, Moro E et al. Parkinson's disease patients with subthalamic stimulation and carers judge quality of life differently. Parkinsonism Relat Disord 2014; 20: 514–519.
16. Martinez-Fernandez R, Pelissier P, Quesada JL, Klinger H, Lhommee E, Schmitt E et al. Postoperative apathy can neutralise benefits in quality of life after subthalamic stimulation for Parkinson's disease. J Neurol Neurosurg Psychiatry 2015; pii: jnnp-2014-310189.
17. Brissaud E. Vingt-troisième leçon. Nature et pathogénie de la maladie de Parkinson. In: Meige H (ed). Leçons sur les maladies nerveuses: la Salpêtrière, 1893-1894. Masson: Paris, France, 1895, pp 488–501.
18. Krack P, Pagonabarraga J, Strafella AP, Kulisevsky J. Apathy: who cares? Lancet Neurol 2015; 14: 465.
19. APA. Diagnostic and Statistical Manual of Mental Disorders—DSM IV, 4th edn. American Psychiatric Association: Washington, DC, USA, 1994.
20. APA Diagnostic and Statistical Manual of Mental Disorders—DSM 5, 5th edn. American Psychiatric publishing: Washington, DC, USA, 2013.
21. Craufurd D, Thompson JC, Snowden JS. Behavioral changes in Huntington Dis-ease. Neuropsychiatry Neuropsychol Behav Neurol 2001; 14: 219–226.
22. van Duijn E, Kingma EM, van der Mast RC. Psychopathology in verified Hun-tington's disease gene carriers. J Neuropsychiatry Clin Neurosci 2007; 19: 441–448.
23. Drijgers RL, Dujardin K, Reijnders JS, Defebvre L, Leentjens AF. Validation of diagnostic criteria for apathy in Parkinson's disease. Parkinsonism Relat Disord 2010; 16: 656–660.
24. Del-Monte J, Capdevielle D, Gely-Nargeot MC, Yazbek H, Pupier F, Boulenger JP et al. [Evolution of the concept of apathy: the need for a multifactorial approach in schizophrenia]. Encephale 2013; 39: S57–S63.
25. Brown RG, Pluck G. Negative symptoms: the 'pathology' of motivation and goal-directed behaviour. Trends Neurosci 2000; 23: 412–417.
26. Pluck GC, Brown RG. Apathy in Parkinson's disease. J Neurol Neurosurg Psychiatry 2002; 73: 636–642.
27. Marin RS, Biedrzycki RC, Firinciogullari S. Reliability and validity of the Apathy Evaluation Scale. Psychiatry Res 1991; 38: 143–162.
28. Belin D, Jonkman S, Dickinson A, Robbins TW, Everitt BJ. Parallel and interactive learning processes within the basal ganglia: relevance for the understanding of addiction. Behav Brain Res 2009; 199: 89–102.
29. Yin HH, Knowlton BJ. The role of the basal ganglia in habit formation. Nat Rev Neurosci 2006; 7: 464–476.
30. Levy R, Dubois B. Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits. Cereb Cortex 2006; 16: 916–928.
31. Schmidt L, d'Arc BF, Lafargue G, Galanaud D, Czernecki V, Grabli D et al. Dis-connecting force from money: effects of basal ganglia damage on incentive motivation. Brain 2008; 131: 1303–1310.
32. Isella V, Melzi P, Grimaldi M, Iurlaro S, Piolti R, Ferrarese C et al. Clinical, neu-ropsychological, and morphometric correlates of apathy in Parkinson's disease. Mov Disord 2002; 17: 366–371.
33. Loas G, Krystkowiak P, Godefroy O. Anhedonia in Parkinson's disease: an over-view. J Neuropsychiatry Clin Neurosci 2012; 24: 444–451.
34. Der-Avakian A, Markou A. The neurobiology of anhedonia and other reward-related deficits. Trends Neurosci 2012; 35: 68–77.
35. Assogna F, Cravello L, Caltagirone C, Spalletta G. Anhedonia in Parkinson's dis-ease: a systematic review of the literature. Mov Disord 2011; 26: 1825–1834.
36. Dujardin K, Langlois C, Plomhause L, Carette AS, Delliaux M, Duhamel A et al. Apathy in untreated early-stage Parkinson disease: relationship with other non-motor symptoms. Mov Disord 2014; 29: 1796–1801.
37. Lhommee E, Klinger H, Thobois S, Schmitt E, Ardouin C, Bichon A et al. Sub-thalamic stimulation in Parkinson's disease: restoring the balance of motivated behaviours. Brain 2012; 135: 1463–1477.
38. Rieu I, Martinez-Martin P, Pereira B, De Chazeron I, Verhagen Metman L, Jahanshahi M et al. International validation of a behavioral scale in Parkinson's disease without dementia. Mov Disord 2015; 30: 705–713.
39. Rodriguez-Oroz MC, Jahanshahi M, Krack P, Litvan I, Macias R, Bezard E et al. Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms. Lancet Neurol 2009; 8: 1128–1139.
40. Schrag A, Horsfall L, Walters K, Noyce A, Petersen I. Prediagnostic presentations of Parkinson's disease in primary care: a case-control study. Lancet Neurol 2015; 14: 57–64.
41. Aarsland D, Bronnick K, Alves G, Tysnes OB, Pedersen KF, Ehrt U et al. The spectrum of neuropsychiatric symptoms in patients with early untreated Parkinson's disease. J Neurol Neurosurg Psychiatry 2009; 80: 928–930.
42. Poewe W. Non-motor symptoms in Parkinson's disease. Eur J Neurol 2008; 15: 14–20.
43. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24: 197–211.
44. Czernecki V, Schupbach M, Yaici S, Levy R, Bardinet E, Yelnik J et al. Apathy following subthalamic stimulation in Parkinson disease: a dopamine responsive symptom. Mov Disord 2008; 23: 964–969.
45. Leentjens AF, Koester J, Fruh B, Shephard DT, Barone P, Houben JJ. The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies. Clin Ther 2009; 31: 89–98.
46. Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, Katzenschlager R et al. The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson's disease. Mov Disord 2011; 26: S42–S80.
47. Thobois S, Lhommee E, Klinger H, Ardouin C, Schmitt E, Bichon A et al. Parkin-sonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil. Brain 2013; 136: 1568–1577.
48. Barone P, Poewe W, Albrecht S, Debieuvre C, Massey D, Rascol O et al. Prami-pexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010; 9: 573–580.
49. Chaudhuri KR, Martinez-Martin P, Antonini A, Brown RG, Friedman JH, Onofrj M et al. Rotigotine and specific non-motor symptoms of Parkinson's disease: post hoc analysis of RECOVER. Parkinsonism Relat Disord 2013; 19: 660–665.
50. Volkmann J, Daniels C, Witt K. Neuropsychiatric effects of subthalamic neuro-stimulation in Parkinson disease. Nat Rev Neurol 2010; 6: 487–498.
51. David R, Koulibaly M, Benoit M, Garcia R, Caci H, Darcourt J et al. Striatal dopamine transporter levels correlate with apathy in neurodegenerative dis-eases. A SPECT study with partial volume effect correction. Clin Neurol Neurosurg 2008; 110: 19–24.
52. Drapier D, Drapier S, Sauleau P, Haegelen C, Raoul S, Biseul I et al. Does sub-thalamic nucleus stimulation induce apathy in Parkinson's disease? J Neurol 2006; 253: 1083–1091.
53. Le Jeune F, Drapier D, Bourguignon A, Peron J, Mesbah H, Drapier S et al. Subthalamic nucleus stimulation in Parkinson disease induces apathy: a PET study. Neurology 2009; 73: 1746–1751.
54. Fleury V, Pollak P, Gere J, Tommasi G, Romito L, Comberscure C et al. Inhibition of levodopa-induced antiakinetic effects secondary to pallidothalamic pathway stimulation. Mov Disord 2016 (in press).
55. Carcenac C, Favier M, Vachez Y, Lacombe E, Carnicella S, Savasta M et al. Sub-thalamic deep brain stimulation differently alters striatal dopaminergic receptor levels in rats. Mov Disord 2015; 30: 1739–1749.
56. Drui G, Carnicella S, Carcenac C, Favier M, Bertrand A, Boulet S et al. Loss of dopaminergic nigrostriatal neurons accounts for the motivational and affective deficits in Parkinson's disease. Mol Psychiatry 2014; 19: 358–367.
57. Lindgren HS, Dunnett SB. Cognitive dysfunction and depression in Parkinson's disease: what can be learned from rodent models? Eur J Neurosci 2012; 35: 1894–1907.
58. Bonito-Oliva A, Masini D, Fisone G. A mouse model of non-motor symptoms in Parkinson's disease: focus on pharmacological interventions targeting affective dysfunctions. Front Behav Neurosci 2014; 8: 290.
59. Bonito-Oliva A, Pignatelli M, Spigolon G, Yoshitake T, Seiler S, Longo F et al. Cognitive impairment and dentate gyrus synaptic dysfunction in experimental parkinsonism. Biol Psychiatry 2014; 75: 701–710.
60. Vuckovic MG, Wood RI, Holschneider DP, Abernathy A, Togasaki DM, Smith A et al. Memory, mood, dopamine, and serotonin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse model of basal ganglia injury. Neurobiol Dis 2008; 32: 319–327.
61. Favier M, Duran T, Carcenac C, Drui G, Savasta M, Carnicella S. Pramipexole reverses Parkinson's disease-related motivational deficits in rats. Mov Disord 2014; 29: 912–920.
62. Carnicella S, Drui G, Boulet S, Carcenac C, Favier M, Duran T et al. Implication of dopamine D3 receptor activation in the reversion of Parkinson's disease-related motivational deficits. Transl Psychiatry 2014; 4: e401.
63. Santiago RM, Barbiero J, Gradowski RW, Bochen S, Lima MM, Da Cunha C et al. Induction of depressive-like behavior by intranigral 6-OHDA is directly correlated with deficits in striatal dopamine and hippocampal serotonin. Behav Brain Res 2014; 259: 70–77.
64. Campos FL, Carvalho MM, Cristovao AC, Je G, Baltazar G, Salgado AJ et al. Rodent models of Parkinson's disease: beyond the motor symptomatology. Front Behav Neurosci 2013; 7: 175.
65. Branchi I, D'Andrea I, Armida M, Cassano T, Pezzola A, Potenza RL et al. Non-motor symptoms in Parkinson's disease: investigating early-phase onset of behavioral dysfunction in the 6-hydroxydopamine-lesioned rat model. J Neurosci Res 2008; 86: 2050–2061.
66. Tadaiesky MT, Dombrowski PA, Figueiredo CP, Cargnin-Ferreira E, Da Cunha C, Takahashi RN. Emotional, cognitive and neurochemical alterations in a premotor stage model of Parkinson's disease. Neuroscience 2008; 156: 830–840.
67. Berghauzen-Maciejewska K, Kuter K, Kolasiewicz W, Glowacka U, Dziubina A, Ossowska K et al. Pramipexole but not imipramine or fluoxetine reverses the "depressive-like" behaviour in a rat model of preclinical stages of Parkinson's disease. Behav Brain Res 2014; 271: 343–353.
68. Chen L, Deltheil T, Turle-Lorenzo N, Liberge M, Rosier C, Watabe I et al. SK channel blockade reverses cognitive and motor deficits induced by nigrostriatal dopamine lesions in rats. Int J Neuropsychopharmacol 2014; 17: 1295–1306.
69. Winter C, von Rumohr A, Mundt A, Petrus D, Klein J, Lee T et al. Lesions of dopaminergic neurons in the substantia nigra pars compacta and in the ventral tegmental area enhance depressive-like behavior in rats. Behav Brain Res 2007; 184: 133–141.
70. Eskow Jaunarajs KL, Angoa-Perez M, Kuhn DM, Bishop C. Potential mechanisms underlying anxiety and depression in Parkinson's disease: consequences of L-DOPA treatment. Neurosci Biobehav Rev 2010; 35: 556–564.
71. Carvalho MM, Campos FL, Coimbra B, Pego JM, Rodrigues C, Lima R et al. Behavioral characterization of the 6-hydroxidopamine model of Parkinson's disease and pharmacological rescuing of non-motor deficits. Mol Neurodegener 2013; 8: 14.
72. Delaville C, Chetrit J, Abdallah K, Morin S, Cardoit L, De Deurwaerdere P et al. Emerging dysfunctions consequent to combined monoaminergic depletions in Parkinsonism. Neurobiol Dis 2012; 45: 763–773.
73. Zhang X, Egeland M, Svenningsson P. Antidepressant-like properties of sarizotan in experimental Parkinsonism. Psychopharmacology (Berl) 2011; 218: 621–634.
74. Hui YP, Wang T, Han LN, Li LB, Sun YN, Liu J et al. Anxiolytic effects of prelimbic 5-HT(1 A) receptor activation in the hemiparkinsonian rat. Behav Brain Res 2015; 277: 211–220.
75. Eskow Jaunarajs KL, George JA, Bishop C. L-DOPA-induced dysregulation of extrastriatal dopamine and serotonin and affective symptoms in a bilateral rat model of Parkinson's disease. Neuroscience 2012; 218: 243–256.
76. Dardou D, Chassain C, Durif F. Chronic pramipexole treatment increases tolerance for sucrose in normal and ventral tegmental lesioned rats. Front Neurosci 2015; 8: 437.
77. Eskow Jaunarajs KL, Dupre KB, Ostock CY, Button T, Deak T, Bishop C. Behavioral and neurochemical effects of chronic L-DOPA treatment on nonmotor sequelae in the hemiparkinsonian rat. Behav Pharmacol 2010; 21: 627–637.
78. Balleine BW, O'Doherty JP. Human and rodent homologies in action control: corticostriatal determinants of goal-directed and habitual action. Neuropsycho-pharmacology 2010; 35: 48–69.
79. Darbaky Y, Forni C, Amalric M, Baunez C. High frequency stimulation of the subthalamic nucleus has beneficial antiparkinsonian effects on motor functions in rats, but less efficiency in a choice reaction time task. Eur J Neurosci 2003; 18: 951–956.
80. Baunez C, Robbins TW. Effects of dopamine depletion of the dorsal striatum and further interaction with subthalamic nucleus lesions in an attentional task in the rat. Neuroscience 1999; 92: 1343–1356.
81. Pioli EY, Meissner W, Sohr R, Gross CE, Bezard E, Bioulac BH. Differential behavioral effects of partial bilateral lesions of ventral tegmental area or substantia nigra pars compacta in rats. Neuroscience 2008; 153: 1213–1224.
82. Baunez C, Amalric M, Robbins TW. Enhanced food-related motivation after bilateral lesions of the subthalamic nucleus. J Neurosci 2002; 22: 562–568.
83. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med 1988; 318: 876–880.
84. Javoy-Agid F, Agid Y. Is the mesocortical dopaminergic system involved in Parkinson disease? Neurology 1980; 30: 1326–1330.
85. Berridge KC. The debate over dopamine's role in reward: the case for incentive salience. Psychopharmacology (Berl) 2007; 191: 391–431.
86. Bromberg-Martin ES, Matsumoto M, Hikosaka O. Dopamine in motivational control: rewarding, aversive, and alerting. Neuron 2010; 68: 815–834.
87. Koob GF, Stinus L, Le Moal M. Hyperactivity and hypoactivity produced by lesions to the mesolimbic dopamine system. Behav Brain Res 1981; 3: 341–359.
88. Le Moal M, Simon H. Mesocorticolimbic dopaminergic network: functional and regulatory roles. Physiol Rev 1991; 71: 155–234.
89. Nieoullon A, Coquerel A. Dopamine: a key regulator to adapt action, emotion, motivation and cognition. Curr Opin Neurol 2003; 16: S3–S9.
90. Castagne V, Moser P, Roux S, Porsolt RD. Rodent models of depression: forced swim and tail suspension behavioral despair tests in rats and mice. Curr Protoc Neurosci 2011; Chapter 8: Unit 8.10A.
91. Nestler EJ, Carlezon WA Jr. The mesolimbic dopamine reward circuit in depression. Biol Psychiatry 2006; 59: 1151–1159.
92. Tye KM, Mirzabekov JJ, Warden MR, Ferenczi EA, Tsai HC, Finkelstein J et al. Dopamine neurons modulate neural encoding and expression of depression-related behaviour. Nature 2013; 493: 537–541.
93. Matheus FC, Rial D, Real JI, Lemos C, Takahashi RN, Bertoglio LJ et al. Temporal dissociation of striatum and prefrontal cortex uncouples anhedonia and defense behaviors relevant to depression in 6-OHDA-lesioned rats. Mol Neurobiol advance online publication, 12 July 2015; e-pub ahead of print.
94. Olds J. Drives and Reinforcements: Behavioral Studies of Hypothalamic Functions. Raven Press: New York, NY, USA, 1977.
95. Salamone JD, Correa M, Farrar A, Mingote SM. Effort-related functions of nucleus accumbens dopamine and associated forebrain circuits. Psychopharmacology (Berl) 2007; 191: 461–482.
96. Sun T, He W, Hu G, Li M. Anxiolytic-like property of risperidone and olanzapine as examined in multiple measures of fear in rats. Pharmacol Biochem Behav 2010; 95: 298–307.
97. Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003; 39: 889–909.
98. Wise RA. Roles for nigrostriatal—not just mesocorticolimbic—dopamine in reward and addiction. Trends Neurosci 2009; 32: 517–524.
99. Beninger RJ, Ranaldi R. Microinjections of flupenthixol into the caudate-putamen but not the nucleus accumbens, amygdala or frontal cortex of rats produce intra-session declines in food-rewarded operant responding. Behav Brain Res 1993; 55: 203–212.
100. Fibiger HC, Zis AP, McGeer EG. Feeding and drinking deficits after 6-hydroxydopamine administration in the rat: similarities to the lateral hypotha-lamic syndrome. Brain Res 1973; 55: 135–148.
101. Ungerstedt U. Adipsia and aphagia after 6-hydroxydopamine induced degen-eration of the nigro-striatal dopamine system. Acta Physiol Scand Suppl 1971; 367: 95–122.
102. Zis AP, Fibiger HC, Phillips AG. Reversal by L-dopa of impaired learning due to destruction of the dopaminergic nigro-neostriatal projection. Science 1974; 185: 960–962.
103. Hollerman JR, Schultz W. Dopamine neurons report an error in the temporal prediction of reward during learning. Nat Neurosci 1998; 1: 304–309.
104. Hollerman JR, Tremblay L, Schultz W. Influence of reward expectation on behavior-related neuronal activity in primate striatum. J Neurophysiol 1998; 80: 947–963.
105. Ilango A, Kesner AJ, Keller KL, Stuber GD, Bonci A, Ikemoto S. Similar roles of substantia nigra and ventral tegmental dopamine neurons in reward and aversion. J Neurosci 2014; 34: 817–822.
106. Rossi MA, Sukharnikova T, Hayrapetyan VY, Yang L, Yin HH. Operant self-stimulation of dopamine neurons in the substantia nigra. PLoS One 2013; 8: e65799.
107. Joyce JN. Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs. Pharmacol Ther 2001; 90: 231–259.
108. Sokoloff P, Diaz J, Le Foll B, Guillin O, Leriche L, Bezard E et al. The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol Disord Drug Targets 2006; 5: 25–43.
109. Bezard E, Ferry S, Mach U, Stark H, Leriche L, Boraud T et al. Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nat Med 2003; 9: 762–767.
110. Bordet R, Ridray S, Carboni S, Diaz J, Sokoloff P, Schwartz JC. Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proc Natl Acad Sci USA 1997; 94: 3363–3367.
111. Jeanblanc J, He DY, McGough NN, Logrip ML, Phamluong K, Janak PH et al. The dopamine D3 receptor is part of a homeostatic pathway regulating ethanol consumption. J Neurosci 2006; 26: 1457–1464.
112. Simpson EH, Winiger V, Biezonski DK, Haq I, Kandel ER, Kellendonk C. Selective overexpression of dopamine D3 receptors in the striatum disrupts motivation but not cognition. Biol Psychiatry 2014; 76: 823–831.
113. Bjorklund A, Dunnett SB. Dopamine neuron systems in the brain: an update. Trends Neurosci 2007; 30: 194–202.
114. Guillin O, Diaz J, Carroll P, Griffon N, Schwartz JC, Sokoloff P. BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization. Nature 2001; 411: 86–89.
115. Cenci MA, Francardo V, O'Sullivan SS, Lindgren HS. Rodent models of impulsive compulsive behaviors in Parkinson's disease: how far have we reached? Neurobiol Dis 2015; 82: 561–573.
116. Seeman P. Parkinson's disease treatment may cause impulse-control disorder via dopamine D3 receptors. Synapse 2015; 69: 183–189.
117. Visanji NP, Gomez-Ramirez J, Johnston TH, Pires D, Voon V, Brotchie JM et al. Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Mov Disord 2006; 21: 1879–1891.
118. Brown CA, Campbell MC, Karimi M, Tabbal SD, Loftin SK, Tian LL et al. Dopamine pathway loss in nucleus accumbens and ventral tegmental area predicts apathetic behavior in MPTP-lesioned monkeys. Exp Neurol 2012; 236: 190–197.
119. Tian L, Xia Y, Flores HP, Campbell MC, Moerlein SM, Perlmutter JS. Neuroimaging analysis of the dopamine basis for apathetic behaviors in an MPTP-lesioned primate model. PLoS One 2015; 10: e0132064.
120. Durand E, Petit O, Tremblay L, Zimmer C, Sgambato-Faure V, Chassain C et al. Social behavioral changes in MPTP-treated monkey model of Parkinson's dis-ease. Front Behav Neurosci 2015; 9: 42.
121. Faggiani E, Delaville C, Benazzouz A. The combined depletion of monoamines alters the effectiveness of subthalamic deep brain stimulation. Neurobiol Dis 2015; 82: 342–348.
122. Lee M, Ryu YH, Cho WG, Kang YW, Lee SJ, Jeon TJ et al. Relationship between dopamine deficit and the expression of depressive behavior resulted from alteration of serotonin system. Synapse 2015; 69: 453–460.
123. Politis M, Niccolini F. Serotonin in Parkinson's disease. Behav Brain Res 2015; 277: 136–145.
124. Haber SN, Knutson B. The reward circuit: linking primate anatomy and human imaging. Neuropsychopharmacology 2010; 35: 4–26.
125. Ikemoto S. Dopamine reward circuitry: two projection systems from the ventral midbrain to the nucleus accumbens-olfactory tubercle complex. Brain Res Rev 2007; 56: 27–78.
126. Ferreira JG, Del-Fava F, Hasue RH, Shammah-Lagnado SJ. Organization of ventral tegmental area projections to the ventral tegmental area-nigral complex in the rat. Neuroscience 2008; 153: 196–213.
127. Belin D, Everitt BJ. Cocaine seeking habits depend upon dopamine-dependent serial connectivity linking the ventral with the dorsal striatum. Neuron 2008; 57: 432–441.
128. Murray JE, Belin-Rauscent A, Simon M, Giuliano C, Benoit-Marand M, Everitt BJ et al. Basolateral and central amygdala differentially recruit and maintain dorso-lateral striatum-dependent cocaine-seeking habits. Nat Commun 2015; 6: 10088.
129. Yelnik J. Modeling the organization of the basal ganglia. Rev Neurol (Paris) 2008; 164: 969–976.
130. Joel D, Niv Y, Ruppin E. Actor-critic models of the basal ganglia: new anatomical and computational perspectives. Neural Netw 2002; 15: 535–547.
131. O'Doherty J, Dayan P, Schultz J, Deichmann R, Friston K, Dolan RJ. Dissociable roles of ventral and dorsal striatum in instrumental conditioning. Science 2004; 304: 452–454.
132. Funkiewiez A, Ardouin C, Krack P, Fraix V, Van Blercom N, Xie J et al. Acute psychotropic effects of bilateral subthalamic nucleus stimulation and levodopa in Parkinson's disease. Mov Disord 2003; 18: 524–530.
133. Krack P, Kumar R, Ardouin C, Dowsey PL, McVicker JM, Benabid AL et al. Mirthful laughter induced by subthalamic nucleus stimulation. Mov Disord 2001; 16: 867–875.
134. Mallet L, Schupbach M, N'Diaye K, Remy P, Bardinet E, Czernecki V et al. Stimulation of subterritories of the subthalamic nucleus reveals its role in the integration of the emotional and motor aspects of behavior. Proc Natl Acad Sci USA 2007; 104: 10661–10666.
135. Welter ML, Schupbach M, Czernecki V, Karachi C, Fernandez-Vidal S, Golmard JL et al. Optimal target localization for subthalamic stimulation in patients with Parkinson disease. Neurology 2014; 82: 1352–1361.
136. Tan SK, Hartung H, Schievink S, Sharp T, Temel Y. High-frequency stimulation of the substantia nigra induces serotonin-dependent depression-like behavior in animal models. Biol Psychiatry 2013; 73: e1–e3.
137. Gradinaru V, Mogri M, Thompson KR, Henderson JM, Deisseroth K. Optical deconstruction of parkinsonian neural circuitry. Science 2009; 324: 354–359.
138. Caudal D, Alvarsson A, Bjorklund A, Svenningsson P. Depressive-like phenotype induced by AAV-mediated overexpression of human alpha-synuclein in mid-brain dopaminergic neurons. Exp Neurol 2015; 273: 243–252.
139. Petit GH, Berkovich E, Hickery M, Kallunki P, Fog K, Fitzer-Attas C et al. Rasagiline ameliorates olfactory deficits in an alpha-synuclein mouse model of Parkinson's disease. PLoS One 2013; 8: e60691.
140. McDowell K, Chesselet MF. Animal models of the non-motor features of Parkinson's disease. Neurobiol Dis 2012; 46: 597–606.
141. Furlanetti LL, Coenen VA, Aranda IA, Dobrossy MD. Chronic deep brain stimulation of the medial forebrain bundle reverses depressive-like behavior in a hemiparkinsonian rodent model. Exp Brain Res 2015; 233: 3073–3085.